
Releases
H.I.G. Capital Exits Clinical Research Firm Celerion in $1.8B Deal
Miami-based investment firm H.I.G. Capital has completed the sale of Celerion Holdings, a global leader in clinical pharmacology, to funds affiliated with THL Partners. The $1.8 billion transaction marks a significant milestone for H.I.G.’s Advantage strategy, which has offloaded three major assets in the last nine months.



























